氘可来昔替尼(Deucravacitinib)耐药了怎么办?

Deucravacitinib resistance can be treated under the guidance of professional physicians by changing other drugs, combination therapy, and the use of biological agents.

氘可来昔替尼(Deucravacitinib)耐药的表现

对产生耐药性可能会表现为治疗效果逐渐减弱，银屑病症状不会像以前那样能够得到有效的控制，红色斑块、鳞屑等表现会加重，也可导致病情反复，疾病进展。

耐药后的处理措施

1、更换其他治疗药物：

可以选择其他针对银屑病和的药物治疗方案，例如其他抑制剂、光疗、外用药物等。 Before switching medications, it is best to have a detailed discussion with your doctor to understand the pros, cons, and indications of each medication so you can make the right choice.

2. Combination therapy:

You can try to combine deuterated colexitinib with other therapeutic drugs to improve the efficacy and reduce the occurrence of drug resistance. For example, deuterated colexitinib can be combined with light therapy or topical medications to achieve better therapeutic effects. Commonly used combination treatments include topical vitamin D3 derivatives and topical corticosteroids, topical vitamin D3 derivatives plus systemic treatment, topical retinoic acid and phototherapy, and topical vitamin D3 derivatives and phototherapy.

3. Use of biological agents:

If deuterated coxitinib and other drug treatment options are ineffective, biological agents can be considered for treatment. Biological agents can more directly regulate the immune system and have better therapeutic effects on psoriasis. Common biological agents include acitretin, methotrexate, cyclosporine A, tripterygium glycosides, immunomodulators, etc.

Deucravacitinib R&D and marketing information

Deucravacitinib (Deucravacitinib) is the world's first oral selective tyrosine kinase 2 (TYK2) allosteric inhibitor developed by Bristol-Myers Squibb Company of the United States. It is used to treat adult patients with moderate to severe plaque psoriasis who are suitable for systemic therapy or phototherapy.

Deuterated colexitinib was approved by the US Food and Drug Administration on September 9, 2022, for the treatment of adult patients with moderate to severe plaque psoriasis who are suitable for systemic treatment or phototherapy. It is the only approved TYK2 inhibitor drug in the world and the first innovative drug for the oral treatment of moderate to severe plaque psoriasis in the past 10 years.

Mechanism of action

Deucravacitinib is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor. It works by selectively binding to the regulatory domain of TYK2, thereby inhibiting TYK2 and its downstream functions. It has significant efficacy in improving skin lesion clearance.

1. Hypersensitivity reactions: Hypersensitivity reactions such as angioedema have been reported. If a clinically significant hypersensitivity reaction occurs, deuterated colexitinib should be discontinued.

2. Infection: Deuterated colexitinib may increase the risk of infection and should be avoided in patients with active or severe infections. If serious infection occurs, discontinue deuterated colexitinib until the infection resolves.

3. Immunization: Avoid use with live vaccines.

4. Abnormal laboratory tests: Periodically evaluate serum triglyceride levels and liver enzymes at baseline and thereafter in patients with known or suspected liver disease.

Recommended hot articles: